A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors

Gene Therapy

Volumn 19, Issue 3, 2012, Pages 271-278

  Quetglas, J I ^a   Fioravanti, J ^a   Ardaiz, N ^a   Medina Echeverz, J ^a   Baraibar, I ^a   Prieto, J ^a,b   Smerdou, C ^a   Berraondo, P ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

antitumor immune response; E7 antigen of human papillomavirus; interferon alpha; Semliki Forest virus; TC 1 tumor

Indexed keywords

LUCIFERASE; PROTEIN E6; PROTEIN E7; RECOMBINANT ALPHA INTERFERON; SEMLIKI FOREST ALPHAVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL STRAIN BHK; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR GROWTH; VIRAL GENE THERAPY; WART VIRUS;

ANIMALS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNITY, CELLULAR; INJECTIONS; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; NEOPLASMS; SEMLIKI FOREST VIRUS;

HUMAN PAPILLOMAVIRUS; MURINAE; MUS; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 84858008258     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.99     Document Type: Article

References (50)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
2. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 1969; 63: 51-57.
3. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997; 8: 343-352. (Pubitemid 27273057)
4. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J et al. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 2002; 21: 1251-1262. (Pubitemid 34185242)
5. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-5161. (Pubitemid 17146488)
6. Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 2010; 43: 244-247.
7. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007; 178: 7540-7549. (Pubitemid 46898022)
8. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174: 4465-4469.
9. Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 2004; 173: 3740-3747. (Pubitemid 39280735)
10. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20: 3703-3718. (Pubitemid 34983231)
11. Shashkova EV, Spencer JF, Wold WS, Doronin K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007; 15: 598-607.
12. Coleman M, Muller S, Quezada A, Mendiratta SK, Wang J, Thull NM et al. Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998; 9: 2223-2230. (Pubitemid 28498008)
13. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14: 299-311.
14. Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I et al. Alpha 1- interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993; 53: 1107-1112. (Pubitemid 23087915)
15. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96: 1553-1558. (Pubitemid 29098489)
16. Salesse S, Moreau-Gaudry F, Pigeonnier-Lagarde V, Mazurier F, Chahine H, Ged C et al. Retroviral vector-mediated transfer of the interferon-alpha gene in chronic myeloid leukemia cells. Cancer Gene Ther 1998; 5: 390-400. (Pubitemid 128640028)
17. Dubrot J, Palazon A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A et al. Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer 2011; 128: 105-118.
18. Narumi K, Kondoh A, Udagawa T, Hara H, Goto N, Ikarashi Y et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci 2010; 101: 1686-1694.
19. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994; 58: 491-562.
20. Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 1991; 9: 1356-1361.
21. Smerdou C, Liljestrom P. Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 1999; 73: 1092-1098. (Pubitemid 29036760)
22. Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008; 10: e33.
23. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004; 22: 70-77. (Pubitemid 38057959)
24. Murphy AM, Morris-Downes MM, Sheahan BJ, Atkins GJ. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Therapy 2000; 7: 1477-1482.
25. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Therapy 2005; 12: 147-159. (Pubitemid 40185918)
26. Colmenero P, Chen M, Castanos-Velez E, Liljestrom P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 2002; 98: 554-560. (Pubitemid 34208556)
27. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki Forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153-163. (Pubitemid 40862367)
28. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Therapy 2005; 12: 1253-1263. (Pubitemid 41195116)
29. Yamanaka R, Zullo SA, Ramsey J, Onodera M, Tanaka R, Blaese M et al. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther 2001; 8: 796-802. (Pubitemid 32983136)
30. Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003; 21: 1082-1088. (Pubitemid 36139938)
31. Barry G, Breakwell L, Fragkoudis R, Attarzadeh-Yazdi G, Rodriguez-Andres J, Kohl A et al. PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J Gen Virol 2009; 90: 1382-1391.
32. Fragkoudis R, Breakwell L, McKimmie C, Boyd A, Barry G, Kohl A et al. The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons. J Gen Virol 2007; 88: 3373-3384. (Pubitemid 350201848)
33. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-4417. (Pubitemid 38375256)
34. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186: 807-815.
35. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540-544.
36. Cooley MA, Blackman MJ, Morris AG. Production of type I (alpha/beta) interferon after virus infection of cloned, alloantigen-sensitized mouse T lymphocytes. Eur J Immunol 1984; 14: 376-379. (Pubitemid 14141646)
37. Nagai Y, Ito Y, Hamaguchi M, Yoshida T, Matsumoto T. Relation of interferon production to the limited replication of Newcastle disease virus in L cells. J Gen Virol 1981; 55: 109-116. (Pubitemid 12240516)
38. Frolova EI, Fayzulin RZ, Cook SH, Griffin DE, Rice CM, Frolov I. Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol 2002; 76: 11254-11264. (Pubitemid 35231280)
39. Casales E, Rodriguez-Madoz JR, Ruiz-Guillen M, Razquin N, Cuevas Y, Prieto J et al. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability. Virology 2008; 376: 242-251.
40. Agapov EV, Frolov I, Lindenbach BD, Pragai BM, Schlesinger S, Rice CM. Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci USA 1998; 95: 12989-12994. (Pubitemid 28509511)
41. Rodriguez-Madoz JR, Liu KH, Quetglas JI, Ruiz-Guillen M, Otano I, Crettaz J et al. Semliki Forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J Virol 2009; 83: 12266-12278.
42. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999; 5: 823-827. (Pubitemid 29318618)
43. He LF, Gu JF, Tang WH, Fan JK, Wei N, Zou WG et al. Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J Gene Med 2008; 10: 983-992.
44. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713-7720.
45. Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 2003; 84: 361-368. (Pubitemid 36175710)
46. Berraondo P, Gonzalez-Aseguinolaza G, Troconiz IF. Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes. Eur J Pharm Sci 2009; 37: 418-426.
47. Liljestrom P, Garoff H. Expression of proteins using Semliki Forest virus vectors. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Smith JA, Seidman JG, Struhl K (eds). Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley Interscience: New York, NY, 1994, pp 16.20.11-16.20.16.
48. Fleeton MN, Sheahan BJ, Gould EA, Atkins GJ, Liljestrom P. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 1999; 80 (Pt 5): 1189-1198. (Pubitemid 29213807)
49. Salminen A, Wahlberg JM, Lobigs M, Liljestrom P, Garoff H. Membrane fusion process of Semliki Forest virus. II: cleavage-dependent reorganization of the spike protein complex controls virus entry. J Cell Biol 1992; 116: 349-357.
50. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67: 8847-8855. (Pubitemid 47437461)